US-based Akebia, which develops treatments for blood cell deficiency disease anemia, has raised a further $4.1m in series B funding, bringing its total financing for the round to more than $26m.
Pharmaceutical research company Akebia Therapeutics secured an additional $4.1m tranche to add to its $22m series B round on Monday from a pool of investors including Novartis Bioventures, a corporate venturing fund belonging to pharmaceutical corporation Novartis.
Additional participants in the round thus far include venture capital (VC) firms Venture Investors, Triathlon Medical Ventures, Athenian Venture Partners, Sigvion Capital and Kearny Venture Partners, and VC fund AgeChem Venture Fund.
The round follows a $28m series A round raised in 2010,…
